ZA963274B - Use of leukemia inhibitory factor and endothelin antagonists. - Google Patents

Use of leukemia inhibitory factor and endothelin antagonists.

Info

Publication number
ZA963274B
ZA963274B ZA9603274A ZA963274A ZA963274B ZA 963274 B ZA963274 B ZA 963274B ZA 9603274 A ZA9603274 A ZA 9603274A ZA 963274 A ZA963274 A ZA 963274A ZA 963274 B ZA963274 B ZA 963274B
Authority
ZA
South Africa
Prior art keywords
inhibitory factor
leukemia inhibitory
endothelin antagonists
antagonist
endothelin
Prior art date
Application number
ZA9603274A
Other languages
English (en)
Inventor
Napoleone Ferrara
Kathleen King
Elizabeth A Luis
Jennie P Mather
Nicolas F Paoni
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA963274B publication Critical patent/ZA963274B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ZA9603274A 1995-04-24 1996-04-24 Use of leukemia inhibitory factor and endothelin antagonists. ZA963274B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42738395A 1995-04-24 1995-04-24

Publications (1)

Publication Number Publication Date
ZA963274B true ZA963274B (en) 1997-10-24

Family

ID=23694642

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9603274A ZA963274B (en) 1995-04-24 1996-04-24 Use of leukemia inhibitory factor and endothelin antagonists.

Country Status (12)

Country Link
EP (2) EP1287832B1 (fr)
JP (1) JPH11504332A (fr)
AT (2) ATE233570T1 (fr)
AU (1) AU702375B2 (fr)
CA (1) CA2214636C (fr)
DE (2) DE69635630T2 (fr)
DK (2) DK0830143T3 (fr)
ES (1) ES2254564T3 (fr)
IL (1) IL117998A (fr)
MX (1) MX9707939A (fr)
WO (1) WO1996033740A1 (fr)
ZA (1) ZA963274B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001404A1 (fr) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services COMPOSITIONS ET PROCEDES DE FECONDATION $i(IN VITRO)
EP1549198A4 (fr) * 2002-09-30 2007-03-28 Univ Duke Atrophie thymique
JP2011231014A (ja) * 2008-08-27 2011-11-17 Keiichi Fukuda 心不全の治療剤
EP2371860A1 (fr) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Anticorps reconnaissant le facteur d'inhibition de la leucémie humaine (LIF) et utilisation d'anticorps anti-LIF pour le traitement de maladies associées à la prolifération de cellules indésirables
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1995008550A1 (fr) * 1993-09-24 1995-03-30 Abbott Laboratories Antagonistes d'endotheline

Also Published As

Publication number Publication date
AU702375B2 (en) 1999-02-18
CA2214636C (fr) 2009-12-22
EP1287832A3 (fr) 2003-04-16
EP0830143B1 (fr) 2003-03-05
EP0830143A1 (fr) 1998-03-25
DE69626510D1 (de) 2003-04-10
WO1996033740A1 (fr) 1996-10-31
MX9707939A (es) 1997-12-31
JPH11504332A (ja) 1999-04-20
DE69635630D1 (de) 2006-01-26
ATE233570T1 (de) 2003-03-15
DE69635630T2 (de) 2006-08-10
DK1287832T3 (da) 2006-05-01
DK0830143T3 (da) 2003-06-16
EP1287832A2 (fr) 2003-03-05
CA2214636A1 (fr) 1996-10-31
IL117998A0 (en) 1996-08-04
ES2254564T3 (es) 2006-06-16
IL117998A (en) 2001-04-30
EP1287832B1 (fr) 2005-12-21
ATE313333T1 (de) 2006-01-15
DE69626510T2 (de) 2003-12-11
AU5665896A (en) 1996-11-18

Similar Documents

Publication Publication Date Title
NZ334270A (en) Glucagon like peptide (GLP-1), analogs and derivatives to treat post surgical catabolic changes and insulin resistance
MY108638A (en) Antiviral nucleoside combination.
MXPA04001525A (es) Analogos de peptido -1 similar al glucagon.
EP0217206A3 (en) Medicament against chronic graft-versus-host diseases, as well as against autoimmune diseases, particularly systemic lupus erythematodes
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
WO2001009138A3 (fr) Antagonistes du recepteur de chimiokine et procedes d'utilisation associes
ITRM920412A0 (it) Eteroprostanoidi, procedimento per la loro preparazione e loro impiegoterapeutico.
CA2111489A1 (fr) Appareil d'electrostimulation musculaire pour gymnastique passive, notamment pour cosmetique faciale
DE68920545D1 (de) Polyolefinlaminat mit hoher Festigkeit und hohem Elastizitätsmodul, das verbesserte Festkörper-Tiefziehfähigkeit aufweist.
GR3024699T3 (en) Use of dideoxy nucleoside analogues in the treatment of viral infections.
IT8983533A0 (it) Dispositivo per la regolazione del frontale nei cassetti
EP0642347A4 (fr) Utilisation de derives de 2-halo adenine comme agents therapeutiques agissant contre la leucemie myeloide chronique.
IL117998A0 (en) Use of leukemia inhibitory factor and endothelin antagonists
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
AU9064191A (en) Use of angiotensin ii receptor antagonists in the treatment of atheroma
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
ES8700940A1 (es) Procedimiento de obtencion de composiciones para el trata- miento de infecciones por rinovirus
FR2700540B1 (fr) alpha-méthyl-(R)-tryptophyl-arylcycloalkylalkylamides ligands aux récepteurs des gastrines, leur préparation et leur utilisation en thérapeutique.
NO981320L (no) Oral anvendelse av (+)-O-demetyltramadol som smertemiddel
AU4449896A (en) Use of beta-cell-tropin (ACTH 22-39) antagonists in the treatment of type II diabetes and associated diseases
AU1067695A (en) Use of lithium compounds in the treatment of cardiac insufficiency
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica
IT8420529A0 (it) N-acetil-s-acil-cisteina adattivita' terapeutica, procedimento per loro preparazione e loro uso in terapia.